Cancer Treatment Reviews
Volume 35, Issue 8 , Pages 707-713 , December 2009

V-ATPase inhibitors and implication in cancer treatment

  • Mario Pérez-Sayáns

      Affiliations

    • Entrerríos s/n, Santiago de Compostela C.P. 15782, Spain
    • Corresponding Author InformationCorresponding author. Address: Facultad de Odontología, Entrerríos s/n, Santiago de Compostela C.P. 15782, Spain. Tel.: +34 626233504; fax: +34 986295424.
    • ,
  • José Manuel Somoza-Martín

      Affiliations

    • Entrerríos s/n, Santiago de Compostela C.P. 15782, Spain
    • Tel.: +34 619099006.
    • ,
  • Francisco Barros-Angueira

      Affiliations

    • Unidad de Medicina Molecular - Fundación Pública Galega de Medicina Xenómica, Edificio de Consultas planta -2, Hospital Clinico Universitario C.P. 15706, Santiago de Compostela, Spain
    • Tel.: +34 981951490.
    • ,
  • José Manuel Gándara Rey

      Affiliations

    • Entrerríos s/n, Santiago de Compostela C.P. 15782, Spain
    • Tel.: +34 639814869.
    • ,
  • Abel García-García

      Affiliations

    • Entrerríos s/n, Santiago de Compostela C.P. 15782, Spain
    • Tel.: +34 606461881.

Received 9 June 2009 ,Revised 3 August 2009 ,Accepted 6 August 2009.

References 

  1. Forgac M. Structure, function and regulation of the vacuolar (H+)-ATPases. FEBS Lett. 1998;440(3):258–263
  2. Nishi T, Forgac M. The vacuolar (H+)-ATPases – nature’s most versatile proton pumps. Nat Rev Mol Cell Biol. 2002;3(2):94–103
  3. Kawasaki-Nishi S, Nishi T, Forgac M. Proton translocation driven by ATP hydrolysis in V-ATPases. FEBS Lett. 2003;545(1):76–85
  4. Finbow ME, Harrison MA. The vacuolar H+ATPase: a universal proton pump of eukaryotes. Biochem J. 1997;324(Pt 3):697–712
  5. Kane PM. Introduction: V-ATPases. J Bioenerg Biomembr. 1999;1(3–5):1992–1998
  6. Stevens TH, Forgac M. Structure, function and regulation of the vacuolar (H+)-ATPase. Annu Rev Cell Dev Biol. 1997;13:779–808
  7. Moriyama Y, Nelson N. H+translocating ATPase in Golgi apparatus. Characterization as vacuolar H+ATPase and its subunit structures. J Biol Chem. 1989;264(31):18445–18450
  8. Schoonderwoert VTG, Holthuis JCM, Tanaka S, Tooze SA, Martens GJM. Inhibition of the vacuolar H+-ATPase perturbs the transport, sorting, processing and release of regulated secretory proteins. Eur J Biochem. 2000;267(17):5646–5654
  9. Martinez-Zaguilan R, Lynch RM, Martinez GM, Gillies RJ. Vacuolar-type H(+)-ATPases are functionally expressed in plasma membranes of human tumor cells. Am J Physiol Cell Physiol. 1993;265(4):C1015–C1029
  10. Fais S, De Milito A, You H, Qin W. Targeting vacuolar H+ATPases as a new strategy against cancer. Cancer Res. 2007;67(22):10627–10630
  11. Bowman EJ, Siebers A, Altendorf K. Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. Proc Natl Acad Sci USA. 1988;85(21):7972–7976
  12. Moriyama Y, Nelson N. Inhibition of vacuolar H+ATPases by fusidic acid and suramin. FEBS Lett. 1988;234(2):383–386
  13. Erickson KL, Beutler JA, Cardellina JH, Boyd MR. Salicylihalamides A and B, novel cytotoxic macrolides from the marine sponge Haliclona sp.. J Org Chem. 1997;62(23):8188–8192
  14. Galinis DL, McKee TC, Pannell LK, Cardellina JH, Boyd MR. Lobatamides A and B, novel cytotoxic macrolides from the Tunicate Aplidium lobatum. J Org Chem. 1997;62(26):8968–8969
  15. Kunze B, Janse R, Sasse F, Höfle G, Reichenbach H. Apicularens A and B, New cytostatic macrolides from Chondromyces species (Myxobacteria): production, physico-chemical and biological properties. J Antibiot Tokyo. 1998;51(12):1075–1080
  16. Gagliardi S, Nadler G, Consolandi E, Parini C, Morvan M, Legave MN, et al. 4-Pentadienamides: novel and selective inhibitors of the vacuolar H+ATPase of osteoclasts with bone antiresorptive activity. J Med Chem. 1998;41(10):1568–1573
  17. Nadler G, Morvan M, Delimoge I, Belfiore P, Zocchetti A, James I, et al. (2Z,4E)-5-(5,6-dichloro-2-indolyl)-2-methoxy-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)-2,4-pentadienamide, a novel, potent and selective inhibitor of the osteoclast V-ATPase. Bioorg Med Chem Lett. 1998;8(24):3621–3626
  18. Kim JW, Shin-Ya K, Furihata K, Hayakawa Y, Seto H. Oximidines I and II: novel antitumor macrolides from Pseudomonas sp.. J Org Chem. 1999;64(1):153–155
  19. Sasse F, Steinmetz H, Hofle G, Reichenbach H. Archazolids, new cytotoxic macrolactones from Archangium gephyra (Myxobacteria). Production, isolation, physico-chemical and biological properties. J Antibiot Tokyo. 2003;56(6):520–525
  20. Shen R, Lin CT, Bowman EJ, Bowman BJ, Porco JA. Lobatamide C: total synthesis, stereochemical assignment, preparation of simplified analogues, and V-ATPase inhibition studies. J Am Chem Soc. 2003;125(26):7889–7901
  21. Kunze B, Steinmetz H, Hofle G, Huss M, Wieczorek H, Reichenbach H. Cruentaren, a new antifungal salicylate-type macrolide from Byssovorax cruenta (myxobacteria) with inhibitory effect on mitochondrial ATPase activity. Fermentation and biological properties. J Antibiot (Tokyo). 2006;59(10):664–668
  22. Petrangolini G, Supino R, Pratesi G, Bo LD, Tortoreto M, Croce AC, et al. Effect of a novel vacuolar-H+ATPase inhibitor on cell and tumor response to camptothecins. J Pharmacol Exp Ther. 2006;318(3):939–946
  23. Saroussi S, Nelson N. Vacuolar H(+)-ATPase-an enzyme for all seasons. Pflugers Arch. 2008;
  24. Niikura K. Effect of a V-ATPase inhibitor, FR202126, in syngeneic mouse model of experimental bone metastasis. Cancer Chemother Pharmacol. 2007;60(4):555–562
  25. Hesselink RW, Fedorov A, Hemminga MA, Prieto M. Membrane-bound peptides from V-ATPase subunit a do not interact with an indole-type inhibitor. J Pept Sci. 2008;14(4):383–388
  26. Forgac M. Structure and function of vacuolar class of ATP-driven proton pumps. Physiol Rev. 1989;69(3):765–796
  27. Finbow ME, Eliopoulos EE, Jackson PJ, Keen JN, Meagher L, Thompson P, et al. Protein Eng. 1992;(1):7–15
  28. Zhang K, Wang ZQ, Gluck S. Identification and partial purification of a cytosolic activator of vacuolar H(+)-ATPases from mammalian kidney. J Biol Chem. 1992;267(14):9701–9705
  29. Zhang K, Wang ZQ, Gluck S . A cytosolic inhibitor of vacuolar H(+)-ATPases from mammalian kidney. J Biol Chem. 1992;267(21):14539–14542
  30. Drose S, Altendorf K. Bafilomycins and concanamycins as inhibitors of V-ATPases and P-ATPases. J Exp Biol. 1997;200(Pt 1):1–8
  31. Muroi M, Shiragami N, Takatsuki A. Destruxin B, a specific and readily reversible inhibitor of vacuolar-type H(+)-translocating ATPase. Biochem Biophys Res Commun. 1994;205(2):1358–1365
  32. Kataoka T, Muroi M, Ohkuma S, Waritani T, Magae J, Takatsuki A, et al. Prodigiosin 25-C uncouples vacuolar type H(+)-ATPase, inhibits vacuolar acidification and affects glycoprotein processing. FEBS Lett. 1995;359(1):53–59
  33. Cantrell CL, Gustafson KR, Cecere MR, Pannell LK, Boyd MR. Chondropsins A and B: novel tumor cell growth-inhibitory macrolide lactams from the marine sponge Chondropsis sp.. J Am Chem Soc. 2000;122(37):8825–8829
  34. Sorensen MG, Henriksen K, Neutzsky-Wulff AV, Dziegiel MH, Karsdal MA. Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption. J Bone Miner Res. 2007;22(10):1640–1648
  35. Zhang J, Feng Y, Forgac M. Proton conduction and bafilomycin binding by the V0 domain of the coated vesicle V-ATPase. J Biol Chem. 1994;269(38):23518–23523
  36. Bowman BJ, Bowman EJ. Mutations in subunit C of the vacuolar ATPase confer resistance to bafilomycin and identify a conserved antibiotic binding site. J Biol Chem. 2002;277(6):3965–3972
  37. Huss M, Ingenhorst G, Konig S, Gassel M, Drose S, Zeeck A, et al. Concanamycin A, the specific inhibitor of V-ATPases, binds to the V(o) subunit c. J Biol Chem. 2002;277(43):40544–40548
  38. Fernandes F, Loura LM, Fedorov A, Dixon N, Kee TP, Prieto M, et al. Binding assays of inhibitors towards selected V-ATPase domains. Biochim Biophys Acta. 2006;1758(11):1777–1786
  39. Bowman BJ, McCall ME, Baertsch R, Bowman EJ. A model for the proteolipid ring and bafilomycin/concanamycin-binding site in the vacuolar ATPase of Neurospora crassa. J Biol Chem. 2006;281(42):31885–31893
  40. Murata T, Kawano M, Igarashi K, Yamato I, Kakinuma Y. Catalytic properties of Na(+)-translocating V-ATPase in Enterococcus hirae. Biochim Biophys Acta. 2001;1505(1):75–81
  41. Bowman EJ, Graham LA, Stevens TH, Bowman BJ. The bafilomycin/concanamycin binding site in subunit c of the V-ATPases from Neurospora crassa and Saccharomyces cerevisiae. J Biol Chem. 2004;279(32):33131–33138
  42. Bowman EJ, Bowman BJ. Cellular role of the V-ATPase in Neurospora crassa: analysis of mutants resistant to concanamycin or lacking the catalytic subunit A. J Exp Biol. 2000;203(Pt 1):97–106
  43. Teplova VV, Tonshin AA, Grigoriev PA, Saris NE, Salkinoja-Salonen MS. Bafilomycin A1 is a potassium ionophore that impairs mitochondrial functions. J Bioenerg Biomembr. 2007;39(4):321–329
  44. Scheidt KA, Bannister TD, Tasaka A, Wendt MD, Savall BM, Fegley GJ, et al. Total synthesis of (−)-Bafilomycin A1. J Am Chem Soc. 2002;124(24):6981–6990
  45. Boyd MR, Farina C, Belfiore P, Gagliardi S, Kim JW, Hayakawa Y, et al. Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-atpases. J Pharmacol Exp Ther. 2001;297(1):114–120
  46. Bowman EJ, Bowman BJ. V-ATPases as drug targets. J Bioenerg Biomembr. 2005;37(6):431–435
  47. Wu Y, Liao X, Wang R, Xie XS, De Brabander JK. Total synthesis and initial structure–function analysis of the potent V-ATPase inhibitors salicylihalamide A and related compounds. J Am Chem Soc. 2002;124(13):3245–3253
  48. Sugimoto Y, Konoki K, Murata M, Matsushita M, Kanazawa H, Oishi T. Design, synthesis, and biological evaluation of fluorinated analogues of salicylihalamide. J Med Chem. 2009;52(3):798–806
  49. Lebreton S, Jaunbergs J, Roth MG, Ferguson DA, De Brabander JK. Evaluating the potential of Vacuolar ATPase inhibitors as anticancer agents and multigram synthesis of the potent salicylihalamide analog saliphenylhalamide. Bioorg Med Chem Lett. 2008;18(22):5879–5883
  50. Huss M, Sasse F, Kunze B, Jansen R, Steinmetz H, Ingenhorst G, et al. Archazolid and apicularen: novel specific V-ATPase inhibitors. BMC Biochem. 2005;6:13
  51. Shen R, Lin CT, Bowman EJ, Bowman BJ, Porco JA. Synthesis and V-ATPase inhibition of simplified lobatamide analogues. Org Lett. 2002;4(18):3103–3106
  52. Kunze B, Sasse F, Wieczorek H, Huss M, Cruentaren A. A highly cytotoxic benzolactone from Myxobacteria is a novel selective inhibitor of mitochondrial F1-ATPases. FEBS Lett. 2007;581(18):3523–3527
  53. Menche D, Hassfeld J, Sasse F, Huss M, Wieczorek H. Design, synthesis, and biological evaluation of novel analogues of archazolid: a highly potent simplified V-ATPase inhibitor. Bioorg Med Chem Lett. 2007;17(6):1732–1735
  54. Roethle PA, Chen IT, D Trauner. Total synthesis of (–)-archazolid B. J Am Chem Soc. 2007;129(29):8960–8961
  55. Hassfeld J, Fares C, Steinmetz H, Carlomagno T, Menche D. Stereochemical determination of Archazolid A and B, highly potent vacuolar-type ATPase inhibitors from the Myxobacterium Archangium gephyra. Org Lett. 2006;8(21):4751–4754
  56. Dixon N, Pali T, Kee TP, Ball S, Harrison MA, Findlay JB, et al. Interaction of spin-labeled inhibitors of the vacuolar H+ATPase with the transmembrane Vo-sector. Biophys J. 2008;94(2):506–514
  57. Pali T, Whyteside G, Dixon N, Kee TP, Ball S, Harrison MA, et al. Interaction of inhibitors of the vacuolar H(+)-ATPase with the transmembrane Vo-sector. Biochemistry. 2004;43(38):12297–12305
  58. Supino R, Petrangolini G, Pratesi G, Tortoreto M, Favini E, Bo LD, et al. Antimetastatic effect of a small-molecule vacuolar H+ATPase inhibitor in in vitro and in vivo preclinical studies. J Pharmacol Exp Ther. 2008;324(1):15–22
  59. Dell’Antone P. Inactivation of H+vacuolar ATPase by the energy blocker 3-bromopyruvate a new antitumour agent. Life Sci. 2006;79(21):2049–2055
  60. Takeda M, Suno-Ikeda C, Shimabukuro K, Yoshida M, Yokoyama K. Mechanism of inhibition of the V-type molecular motor by tributyltin chloride. Biophys J. 2009;96(3):1210–1217
  61. Niikura K, Nakajima S, Takano M, Yamazaki H. FR177995, a novel vacuolar ATPase inhibitor, exerts not only an inhibitory effect on bone destruction but also anti-immunoinflammatory effects in adjuvant-induced arthritic rats. Bone. 2007;(4):888–894
  62. Niikura K, Takano M, Sawada M. A novel inhibitor of vacuolar ATPase, FR167356, which can discriminate between osteoclast vacuolar ATPase and lysosomal vacuolar ATPase. Br J Pharmacol. 2004;142(3):558–566
  63. McLean LA, Roscoe J, Jorgensen NK, Gorin FA, Cala PM. Malignant gliomas display altered pH regulation by NHE1 compared with nontransformed astrocytes. Am J Physiol Cell Physiol. 2000;278(4):C676–C888
  64. Cardone RA, Casavola V, Reshkin SJ. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat Rev Cancer. 2005;5(10):786–795
  65. Perona R, Serrano R. Increased pH and tumorigenicity of fibroblasts expressing a yeast proton pump. Nature. 1988;334(6181):438–440
  66. Sennoune SR, Martinez-Zaguilan R. Plasmalemmal vacuolar H+ATPases in angiogenesis diabetes and cancer. J Bioenerg Biomembr. 2007;39(5–6):427–433
  67. Montcourrier P, Silver I, Farnoud R, Bird I, Rochefort H. Breast cancer cells have a high capacity to acidify extracellular milieu by a dual mechanism. Clin Exp Metastasis. 1997;15(4):382–392
  68. Parkins CS, Stratford MR, Dennis MF, Stubbs M, Chaplin DJ. The relationship between extracellular lactate and tumour pH in a murine tumour model of ischaemia-reperfusion. Br J Cancer. 1997;75(3):319–323
  69. Martinez-Zaguilan R, Seftor EA, Seftor RE, Chu YW, Gillies RJ, Hendrix MJ. Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis. 1996;14(2):176–186
  70. Rofstad EK, Mathiesen B, Kindem K, Galappathi K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res. 2006;66(13):6699–6707
  71. Montcourrier P, Mangeat PH, Valembois C, Salazar G, Sahuquet A, Duperray C, et al. Characterization of very acidic phagosomes in breast cancer cells and their association with invasion. J Cell Sci. 1994;107(Pt 9):2381–2391
  72. Rozhin J, Sameni M, Ziegler G, Sloane BF. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res. 1994;54(24):6517–6525
  73. Johnson LL, Pavlovsky AG, Johnson AR, Janowicz JA, Man CF, Ortwine DF, et al. A rationalization of the acidic pH dependence for stromelysin-1 (matrix metalloproteinase-3) catalysis and inhibition. J Biol Chem. 2000;275(15):11026–11033
  74. Kato Y, Lambert CA, Colige AC, Mineur P, Noel A, Frankenne F, et al. Acidic extracellular pH induces matrix metalloproteinase-9 expression in mouse metastatic melanoma cells through the phospholipase d-mitogen-activated protein kinase signaling. J Biol Chem. 2005;280(12):10938–10944
  75. Gocheva V, Joyce JA. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle. 2007;6(1):60–64
  76. Sennoune SR, Bakunts K, Martinez GM, Chua-Tuan JL, Kebir Y, Attaya MN, et al. Vacuolar H+ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. Am J Physiol Cell Physiol. 2004;286(6):C1443–C1452
  77. Lu X, Qin W, Li J, Tan N, Pan D, Zhang H, et al. The Growth and Metastasis of Human Hepatocellular Carcinoma Xenografts Are Inhibited by Small Interfering RNA Targeting to the Subunit ATP6L of Proton Pump. Cancer Res. 2005;65(15):6843–6849
  78. Halaban R, Patton RS, Cheng E, Svedine S, Trombetta ES, Wahl ML, et al. Abnormal acidification of melanoma cells induces tyrosinase retention in the early secretory pathway. J Biol Chem. 2002;277(17):14821–14828
  79. Nanda A, Brumell JH, Nordstrom T, Kjeldsen L, Sengelov H, Borregaard N, et al. Activation of proton pumping in human neutrophils occurs by exocytosis of vesicles bearing vacuolar-type H+ATPases. J Biol Chem. 1996;271(27):15963–15970
  80. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer. 2004;4(11):891–899
  81. Volk C, Albert T, Kempski OS. A proton-translocating H+ATPase is involved in C6 glial pH regulation. Biochim Biophys Acta. 1998;1372(1):28–36
  82. McSheehy PM, Troy H, Kelland LR, Judson IR, Leach MO, Griffiths JR. Increased tumour extracellular pH induced by Bafilomycin A1 inhibits tumour growth and mitosis in vivo and alters 5-fluorouracil pharmacokinetics. Eur J Cancer. 2003;39(4):532–540
  83. Zhong H, De Marzo AM, Laughner E, Lim M, DA Hilton, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999;59(22):5830–5835
  84. Lim JH, Park JW, Kim MS, Park SK, Johnson RS, Chun YS. Bafilomycin induces the p21-mediated growth inhibition of cancer cells under hypoxic conditions by expressing hypoxia-inducible factor-1alpha. Mol Pharmacol. 2006;70(6):1856–1865
  85. Ohta T, Arakawa H, Futagami F, Fushida S, Kitagawa H, Kayahara M, et al. Bafilomycin A1 induces apoptosis in the human pancreatic cancer cell line Capan-1. J Pathol. 1998;185(3):324–330
  86. Aiko K, Tsujisawa T, Koseki T, Hashimoto S, Morimoto Y, Amagasa T, et al. Involvement of cytochrome c and caspases in apoptotic cell death of human submandibular gland ductal cells induced by concanamycin A. Cell Signal. 2002;14(8):717–722
  87. De Milito A, Iessi E, Logozzi M, Lozupone F, Spada M, Marino ML, et al. Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res. 2007;67(11):5408–5417
  88. Gottlieb RA, Giesing HA, Zhu JY, Engler RL, Babior BM. Cell acidification in apoptosis: granulocyte colony-stimulating factor delays programmed cell death in neutrophils by up-regulating the vacuolar H(+)-ATPase. Proc Natl Acad Sci USA. 1995;92(13):5965–5968
  89. Xu J, Feng HT, Wang C, Yip KH, Pavlos N, Papadimitriou JM, et al. Effects of Bafilomycin A1: an inhibitor of vacuolar H (+)-ATPases on endocytosis and apoptosis in RAW cells and RAW cell-derived osteoclasts. J Cell Biochem. 2003;88(6):1256–1264
  90. Morimura T, Fujita K, Akita M, Nagashima M, Satomi A. The proton pump inhibitor inhibits cell growth and induces apoptosis in human hepatoblastoma. Pediatr Surg Int. 2008;24(10):1087–1094
  91. Nakashima S, Hiraku Y, Tada-Oikawa S, Hishita T, Gabazza EC, Tamaki S. et al. Vacuolar H+ATPase inhibitor induces apoptosis via lysosomal dysfunction in the human gastric cancer cell line MKN-1. J Biochem. 2003;134(3):359–364
  92. Hishita T, Tada-Oikawa S, Tohyama K, Miura Y, Nishihara T, Tohyama Y, et al. Caspase-3 activation by lysosomal enzymes in cytochrome c-independent apoptosis in myelodysplastic syndrome-derived cell line P39. Cancer Res. 2001;61(7):2878–2884
  93. Wu YC, Wu WKK, Li Y, Yu L, Li ZJ, Wong CCM, et al. Inhibition of macroautophagy by bafilomycin A1 lowers proliferation and induces apoptosis in colon cancer cells. Biochem Biophys Res Commun. 2009;382(2):451–456
  94. Meijer AJ, Codogno P. Regulation and role of autophagy in mammalian cells. Int J Biochem Cell Biol. 2004;36(12):2445–2462
  95. Mortimore GE, Hutson NJ, Surmacz CA. Quantitative correlation between proteolysis and macro- and microautophagy in mouse hepatocytes during starvation and refeeding. Proc Natl Acad Sci USA. 1983;80(8):2179–2183
  96. Martinez-Munoz GA, Kane P. Vacuolar and plasma membrane proton pumps collaborate to achieve cytosolic pH homeostasis in yeast. J Biol Chem. 2008;283(29):20309–20319
  97. Lyons JC, Kim GE, Song CW. Modification of intracellular pH and thermosensitivity. Radiat Res. 1992;129(1):79–87
  98. Hayashi Y, Katayama K, Togawa T, Kimura T, Yamaguchi A. Effects of bafilomycin A1 a vacuolar type H+ ATPase inhibitor on the thermosensitivity of a human pancreatic cancer cell line. Int J Hyperthermia. 2006;22(4):275–285
  99. Ohta T, Arakawa H, Futagami F, Fushida S, Kitagawa H, Kayahara M, et al. A new strategy for the therapy of pancreatic cancer by proton pump inhibitor. Gan To Kagaku Ryoho. 1996;(12):1660–1664
  100. Murakami T, Shibuya I, Ise T, Chen ZS, Akiyama S, Nakagawa M, et al. Elevated expression of vacuolar proton pump genes and cellular PH in cisplatin resistance. Int J Cancer. 2001;93(6):869–874
  101. Torigoe T, Izumi H, Ise T, Murakami T, Uramoto H, Ishiguchi H, et al. Vacuolar H(+)-ATPase: functional mechanisms and potential as a target for cancer chemotherapy. Anticancer Drugs. 2002;(3):237–243
  102. Torigoe T, Izumi H, Ishiguchi H, Uramoto H, Murakami T, Ise T, et al. Enhanced expression of the human vacuolar H+ATPase c subunit gene (ATP6L) in response to anticancer agents. J Biol Chem. 2002;277(39):36534–36543
  103. Sennoune SR, Luo D, Martinez-Zaguilan R. Plasmalemmal vacuolar-type H+ATPase in cancer biology. Cell Biochem Biophys. 2004;40(2):185–206
  104. Perez-Sayans M, Garcia-Garcia A, Reboiras-Lopez MD, Gandara-Vila P. Role of V-ATPases in solid tumors: Importance of the subunit C (Review). Int J Oncol. 2009;34(6):1513–1520
  105. Hinton A, Bond S, Forgac M. V-ATPase functions in normal and disease processes. Pflugers Arch. 2009;457(3):589–598
  106. Hilgenbrink AR, Low PS. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J Pharm Sci. 2005;94(10):2135–2146
  107. Huss M, Wieczorek H. Inhibitors of V-ATPases: old and new players. J Exp Biol. 2009;212(Pt 3):341–346

PII: S0305-7372(09)00119-4

doi: 10.1016/j.ctrv.2009.08.003

Cancer Treatment Reviews
Volume 35, Issue 8 , Pages 707-713 , December 2009

Article Tools

* Image Usage & Resolution